Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00563992 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder
A Phase 1 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT00563992 is a Phase 1 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 98 participants.
The verdict
NCT00563992, a Phase 1 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This study will evaluate the effectiveness of two different mood stabilizing medications, lithium and valproate, in treating people with bipolar disorder and suicidal behavior.
Interventions
- DRUG Lithium
- DRUG Valproic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2001-01 |
| Est. Completion | 2008-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00563992
The ClinicalTrials.gov registry entry for NCT00563992 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lithium is the first listed.
NCT00563992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00563992 about?
NCT00563992 is a clinical study titled "Effectiveness of Lithium and Valproate in Treating High-Risk Bipolar Disorder". This study will evaluate the effectiveness of two different mood stabilizing medications, lithium and valproate, in treating people with bipolar disorder and suicidal behavior.
What is the current status of trial NCT00563992?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2001-01. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00563992?
The interventions under investigation include: Lithium (DRUG), Valproic acid (DRUG).
Who is sponsoring clinical trial NCT00563992?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.